Analyzing The Drugs Selected For The 2028 Medicare Drug Price Negotiation Cycle

Forefront Group 2026 Dataset

View at publisher
Authors: Kristi Martin, Rachel Sachs
DOI: 10.1377/forefront.20260204.666780
Cited by: 0

Abstract

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity to revisit prices previously negotiated.

Fields of Study & Subjects

Pharmaceutical Economics and Policy Healthcare Policy and Management Health Systems Economic Evaluations Quality of Life

Publication details

Journal / source
Forefront Group
Publication date
5 February 2026
Document type
Dataset